Zoe Marjenberg

Zoe Marjenberg

Auto-generated profile, based on publicly available information

Zoe Marjenberg

Maverex Ltd, Newcastle-upon-Tyne

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
HMHana Müllerová
Hana Müllerová
JMJonathan Marshall
Jonathan Marshall
ENEnrico de Nigris
Enrico de Nigris
PVPrecil Varghese
Precil Varghese
NPNick Pooley
Nick Pooley
ZMZoe Marjenberg
Zoe Marjenberg
Background: The majority of patients with chronic obstructive pulmonary disease (COPD) suffer from comorbid cardiovascular (CV) disease. Accumulating evidence suggests a temporal association between COPD exacerbations and acute CV events, possibly due to lung hyperinflation, increased hypoxemia and systemic inflammation. The aims of the study were to estimate the risk of (1) acute CV events [acute myocardial infarction (AMI), CV-related death] or stroke in the months following a COPD exacerbation and (2) COPD exacerbation in the months following an acute CV event. Methods: A systematic literature review of observational studies published since 2000 was conducted by searching literature databases (Medline and Embase). Studies were eligible if conducted in adults with COPD, exposed to either COPD exacerbation or acute CV events, with outcomes of acute CV events or COPD exacerbation reported. Studies were appraised for relevance, bias and quality. Meta-analyses, using random-effect models, were performed for each outcome of interest, thus providing a pooled relative risk (RR) and its 95% confidence interval. Results: Eight studies were identified, of which seven were used for the meta-analyses examining the risk of CV events 1–3 months after an exacerbation compared with none. For stroke (six studies), RR was 1.68 (95% CI = 1.19–2.38). For AMI (six studies), RR was 2.43 (95% CI = 1.40–4.20). No studies exploring risk of exacerbation following an acute CV event were identified. Conclusion: This meta-analysis identified a markedly increased risk of stroke or AMI within a relatively short period of time following a COPD exacerbation. Although the underlying mechanisms are not fully elucidated, patients with COPD should be monitored for risk of CV outcomes after exacerbations. In addition, preventing exacerbations may decrease the risk of subsequent acute CV events. Registration: The study protocol was published via PROSPERO: International Prospective Register of Systematic Reviews (#CRD42020211055).

9 September 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
ZMZoe Marjenberg
Zoe Marjenberg
CWCiara Wright
Ciara Wright
NPNick Pooley
Nick Pooley
KCKa Wang Cheung
Ka Wang Cheung
yusuke shimakawayusuke shimakawa
yusuke shimakawa
EVEmmanuel Vidor
Emmanuel Vidor
Infant vaccination against the hepatitis B virus began in the World Health Organization South East Asia Region and the Western Pacific Region between 1983 and 2016. This systematic review examined the seroprevalence of hepatitis B surface antigen (HBsAg) in children and the rate of mother-to-child transmission (MTCT) in these regions between 1990 and 2020. MEDLINE and EMBASE were searched for articles published between January 1990 and September 2020, which reported seroprevalence of HBsAg in children aged 0-15 years and/or the rate of MTCT in the South East Asia Region and Western Pacific Region. A pragmatic review identified supporting information. This review was registered in the International Prospective Register of Systematic Reviews (#CRD42020211707). Of 115 included studies, 77 (24 countries) reported HBsAg prevalence, and 38 (nine countries) reported MTCT. The seroprevalence of HBsAg ranged between 0.0% and 27.4%, with a decreasing trend over time in each country. MTCT rates were 0.0-5.2% in infants of mothers who are hepatitis B e antigen-negative and 2.7-53.0% in infants of mothers who are hepatitis B e antigen-positive. After the introduction of infant hepatitis B virus vaccination programs, the countries in South East Asia Region and Western Pacific Region observed a reduction in HBsAg seroprevalence in children. Nevertheless, the risk of MTCT persists, emphasizing the importance of antenatal screening to identify high-risk pregnancies.

12 September 2025 in European Journal of Integrative Medicine
Verified
Journal Article
Closed access
JXJiaxin Xu
Jiaxin Xu
PZPeng Zhang
Peng Zhang
JYJianya Yang
Jianya Yang
YXYang Xie
Yang Xie
DHDonghui Huang
Donghui Huang
SLSuyun Li
Suyun Li

22 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SHStephane Heymans
Stephane Heymans
BHBettina Heidecker
Bettina Heidecker
ZMZoe Marjenberg
Zoe Marjenberg
RGRhiannon Green
Rhiannon Green
TPTriantafyllos Pliakasf
Triantafyllos Pliakasf
SASultan Abduljawad
Sultan Abduljawad
Background and Aims: SARS-CoV-2 infection is associated with an increased risk of cardiovascular, cerebrovascular and venous thromboembolism events. We aimed to assess the impact of COVID-19 vaccination prior to SARS-CoV-2 infection on the risk of these events post-infection. Methods: Embase and MEDLINE were searched from January 2021 to 11 September 2025, supplemented by citation searching. Observational studies were included if they reported risks of cardiovascular, cerebrovascular, or venous thromboembolic events after SARS-CoV-2 infection between different vaccination groups (e.g. unvaccinated, vaccinated, or booster vaccinated), or reported risk of events after SARS-CoV-2 infection compared with no infection, stratified by vaccination status. Random-effects meta-analyses were conducted to estimate pooled hazard ratios (HRs) comparing vaccinated and unvaccinated individuals across prespecified outcomes. Results: Twenty-three studies were included in the systematic review; most reported an association between vaccination and a reduced risk of post-infection vascular events. Ten studies were included across meta-analyses comparing vaccinated and unvaccinated individuals. Pre-infection vaccination was associated with significantly reduced risks of composite cardiovascular/cerebrovascular events (HR 0.60, 95% confidence intervals [CI] 0.51–0.69), stroke (HR 0.75, 95% CI 0.64–0.88), acute coronary syndrome (HR 0.70, 95% CI 0.52–0.95), arrhythmias (HR 0.82, 95% CI 0.69–0.98), and venous thromboembolism (HR 0.51, 95% CI 0.36–0.73). No statistically significant reduction was observed for heart failure (HR 0.72 [95% CI 0.47–1.10]). Conclusions: Pre-infection COVID-19 vaccination is associated with lower risks of cardiovascular, cerebrovascular and venous thromboembolism events following SARS-CoV-2 infection in the pre- and post-Omicron eras, supporting its role within broader prevention strategies.